{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:05:33Z","timestamp":1753877133165,"version":"3.41.2"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:00:00Z","timestamp":1571184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Red de Investigaci\u00f3n en SIDA","award":["RD16\/0025\/0020-ISCIII-FEDER"],"award-info":[{"award-number":["RD16\/0025\/0020-ISCIII-FEDER"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01298"],"award-info":[{"award-number":["PI18\/01298"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To analyse whether integrase inhibitor (InSTI)-based regimens achieve better immunological recovery than NNRTI- or boosted PI (bPI)-based regimens as initial ART.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a retrospective analysis, we selected patients who initiated ART with two NRTIs plus an InSTI, an NNRTI or a bPI and maintained both the same \u2018third drug\u2019 and an HIV-RNA &lt;50\u2009copies\/mL in \u226595% of determinations once undetectable viral load had been achieved. We compared CD4+ count, %CD4+ and CD4+\/CD8+ ratio recovery over 2\u2009years. Data were analysed using mixed-effects regression models for repeated measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 836 patients included, 208, 481 and 147 initiated with InSTI, NNRTI and bPI, respectively. For CD4+, %CD4+ and CD4+\/CD8+ two main slopes were identified: from month 0 to month 6, with the highest increments; and from month 6 to month 24, with smaller increases every semester. Although the patients on InSTI achieved undetectable viral load faster, for CD4+ and %CD4+ there were no differences in the slopes of change according to the third drug either for the first phase (P = 0.137 and P = 0.393, respectively) or from month 6 onwards (P = 0.834 and P = 0.159, respectively). The increase in CD4+\/CD8+ was slightly higher for bPI compared with InSTI (difference of 0.0119, 95% CI 0.0020\u20130.0205; P = 0.018), but clinically negligible. From month 6 onwards, no differences were found between treatment groups (P = 0.176).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Immune restoration measured as CD4+ count, %CD4+ and CD4+\/CD8+ increases was independent of the third antiretroviral drug class used when given with two NRTIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz421","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:52:05Z","timestamp":1568634725000},"source":"Crossref","is-referenced-by-count":4,"title":["Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?"],"prefix":"10.1093","author":[{"given":"Yusnelkis","family":"Milan\u00e9s-Guisado","sequence":"first","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-1574","authenticated-orcid":false,"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Mu\u00f1oz-Pichardo","sequence":"additional","affiliation":[{"name":"Departamento de Estad\u00edstica e I.O., Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[{"name":"Hospital Universitario Reina Sof\u00eda\/Instituto Maimonides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba\/Universidad de C\u00f3rdoba, C\u00f3rdoba, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Trujillo-Rodriguez","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Roca-Oporto","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda Cl\u00ednica y Medicina Preventiva, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,16]]},"reference":[{"key":"2019101610290329800_dkz421-B1"},{"key":"2019101610290329800_dkz421-B2"},{"key":"2019101610290329800_dkz421-B3","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"2019101610290329800_dkz421-B4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1\u2013infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019101610290329800_dkz421-B5","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2019101610290329800_dkz421-B6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00126334-200311010-00016","article-title":"CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study","volume":"34","author":"Wood","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019101610290329800_dkz421-B7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/jac\/dkh329","article-title":"A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts","volume":"54","author":"Waters","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2019101610290329800_dkz421-B8","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(06)69861-9","article-title":"A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial","volume":"368","author":"MacArthur","year":"2006","journal-title":"Lancet"},{"key":"2019101610290329800_dkz421-B9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000226789.51992.3f","article-title":"Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384","volume":"42","author":"Gandhi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019101610290329800_dkz421-B10","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/592113","article-title":"CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy","volume":"47","author":"Khanna","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019101610290329800_dkz421-B11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/QAI.0000000000000567","article-title":"Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1-infected patients starting efavirenz, lopinavir\u2013ritonavir, or atazanavir\u2013ritonavir plus tenofovir\/emtricitabine","volume":"69","author":"Miro","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019101610290329800_dkz421-B12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"2019101610290329800_dkz421-B13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cid\/ciw236","article-title":"Nonnucleoside reverse-transcriptase inhibitor- vs ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematic review and metaanalysis of randomized trials","volume":"63","author":"Borges","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019101610290329800_dkz421-B14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkw375","article-title":"Different impact of raltegravir versus efavirenz on CD4\/CD8 ratio recovery in HIV-infected patients","volume":"72","author":"Serrano-Villar","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019101610290329800_dkz421-B15","doi-asserted-by":"crossref","first-page":"e0205777.","DOI":"10.1371\/journal.pone.0205777","article-title":"Absolute CD4+ T cell count overstate immune recovery assessed by CD4+\/CD8+ ratio in HIV-infected patients on treatment","volume":"13","author":"Milan\u00e9s-Guisado","year":"2018","journal-title":"PLoS One"},{"key":"2019101610290329800_dkz421-B16","doi-asserted-by":"crossref","first-page":"e0171155.","DOI":"10.1371\/journal.pone.0171155","article-title":"Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification","volume":"12","author":"Lima","year":"2017","journal-title":"PLoS One"},{"key":"2019101610290329800_dkz421-B17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/QAI.0b013e31819e721b","article-title":"Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay","volume":"51","author":"Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019101610290329800_dkz421-B18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/B978-0-12-381479-1.00012-5","volume-title":"Data Mining: Concepts and Techniques","author":"Han","year":"2012"},{"key":"2019101610290329800_dkz421-B19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e318225ba62","article-title":"CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts","volume":"58","author":"Wright","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019101610290329800_dkz421-B20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00002030-200109280-00008","article-title":"Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study","volume":"15","author":"Friedl","year":"2001","journal-title":"AIDS"},{"key":"2019101610290329800_dkz421-B21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00002030-200201250-00014","article-title":"Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides","volume":"16","author":"Barreiro","year":"2002","journal-title":"AIDS"},{"key":"2019101610290329800_dkz421-B22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/aid.2009.0105","article-title":"Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial","volume":"26","author":"Mir\u00f3","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019101610290329800_dkz421-B23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1468-1293.2004.00188.x","article-title":"Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy","volume":"5","author":"van Leth","year":"2004","journal-title":"HIV Med"},{"key":"2019101610290329800_dkz421-B24","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1097\/QAD.0000000000001668","article-title":"Virologic suppression and CD4 cell count recovery after initiation of raltegravir- or efavirenz-containing HIV treatment regimens","volume":"32","author":"Edwards","year":"2017","journal-title":"AIDS"},{"key":"2019101610290329800_dkz421-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0140519","article-title":"Antiretroviral regimens and CD4\/CD8 ratio normalization in HIV-infected patients during the initial year of treatment: a cohort study","volume":"10","author":"De Salvador-Guillou\u00ebt","year":"2015","journal-title":"PLoS One"},{"key":"2019101610290329800_dkz421-B26","doi-asserted-by":"crossref","first-page":"e3108.","DOI":"10.1097\/MD.0000000000003108","article-title":"Comparative impact of suppressive antiretroviral regimens on the CD4\/CD8 T-cell ratio: a cohort study","volume":"95","author":"Masi\u00e1","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz421\/30157492\/dkz421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz421\/30157492\/dkz421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T21:07:14Z","timestamp":1571260034000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkz421\/5588581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,16]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz421","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published":{"date-parts":[[2019,10,16]]},"article-number":"dkz421"}}